Research Progress on Proprotein Convertase Subtilisin/Kexin Type 9-mediated Atherosclerotic Inflammatory Response and Intervention of Traditional Chinese Medicine
Keywords:
Proprotein convertase subtilisin/kexin type 9, Atherosclerosis, Inflammatory response, Cell adhesion, Interleukin, Toll-like receptor 4, Nuclear factor KB, Traditional Chinese medicineAbstract
The “cholesterol theory” has laid the foundation for the treatment of atherosclerotic cardiovascular diseases, but research has proven that the “inflammatory response theory” is another research hotspot related to atherosclerosis (AS) and a potential target for AS intervention. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has pleiotropic effects mediated by lipid regulation and inflammatory response. It can drive inflammatory responses through lipids and is also an independent inflammatory mediator involved in the occurrence of AS. The inflammatory response effect of PCSK9 may be one of the important targets of traditional Chinese medicine for the treatment of AS. Traditional Chinese medicines and their extracts (quercetin, berberine hydrochloride, gynostemma pentaphyllum, curcumin, 10-dehydrogingerdione and sugarcane element, ginkgolide B, naringin, and hesperidin, etc.), and traditional Chinese medicine compounds (Shoushen granules, Qizhi Tongmai granules, etc.) have inhibitory effects on Pcsk9, which is an important direction for PCSK9 drug research and discovery.
References
Vos T, Lim S, Abbafati C, et al., 2020, Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258): 1204–1222.
Grundy SM, Stone NJ, Bailey AL, et al., 2019, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25): e1082–e1143.
Matsuura Y, Kanter JE, Bornfeldt KE, 2019, Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(1): e1–e9.
Ross R, 1999, Atherosclerosis – An Inflammatory Disease. The New England Journal of Medicine, 340(2): 115–126.
Ridker PM, Everett BM, Thuren T, et al., 2017, Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377(12): 1119–1131.
Tardif JC, Kouz S, Waters DD, et al., 2019, Efficacy and Safety of Low-dose Colchicine after Myocardial Infarction. The New England Journal of Medicine, 381(26): 2497–2505.
Nidorf SM, Fiolet ATL, Mosterd A, et al., 2020, Colchicine in Patients with Chronic Coronary Disease. The New England Journal of Medicine, 383(19): 1838–1847.
Abifadel M, Varret M, Rabès JP, et al., 2003, Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia. Nature Genetics, 34(2): 154–156.
Piper DE, Jackson S, Liu Q, et al., 2007, The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol. Structure, 15(5): 545–552.
Cohen J, Pertsemlidis A, Kotowski IK, et al., 2005, Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9. Nature Genetics, 37(2): 161–165.
Cohen JC, Boerwinkle E, Mosley TH, et al., 2006, Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. The New England Journal of Medicine, 354(12): 1264–1272.
Sabatine MS, Giugliano RP, Keecha C, et al., 2017, Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376(18): 1713–1722.
Ray KK, Wright RS, Kallend D, et al., 2020, Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine, 382(16): 1507–1519.
Schwartz GG, Steg PG, Szarek M, et al., 2018, Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379(22): 2097–2107.
Luquero A, Badimon L, Borrell-Pages M, 2021, PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation. Frontiers in Cardiovascular Medicine, 8: 639727.
Yurtseven E, Ural D, Baysal K, et al., 2020, An Update on the Role of PCSK9 in Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 27(9): 909–918.
Drechsler M, Megens RT, Van ZM, et al., 2010, Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis. Circulation, 122(18): 1837–1845.
Louloudis G, Ambrosini S, Paneni F, et al., 2021, Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State. Frontiers in Cardiovascular Medicine, 8: 718741.
Grune J, Meyborg H, Bezhaeva T, et al., 2017, PCSK9 Regulates the Chemokine Receptor CCR2 on Monocytes. Biochemical and Biophysical Research Communications, 485(2): 312–318.
Badimon L, Luquero A, Crespo J, et al., 2021, PCSK9 and LRP5 in Macrophage Lipid Internalization and Inflammation. Cardiovascular Research, 117(9): 2054–2068.
Chistiakov DA, Bobryshev YV, Orekhov AN, 2015, Neutrophil’s Weapons in Atherosclerosis. Experimental and Molecular Pathology, 99(3): 663–671.
Tall AR, Westerterp M, 2019, Inflammasomes, Neutrophil Extracellular Traps, and Cholesterol. Journal of Lipid Research, 60(4): 721–727.
Sun H, Krauss RM, Chang JT, et al., 2018, PCSK9 Deficiency Reduces Atherosclerosis, Apolipoprotein B Secretion, and Endothelial Dysfunction. Journal of Lipid Research, 59(2): 207–223.
Zufeng D, Shijie L, Xianwei W, et al., 2015, Cross-Talk Between LOX-1 and PCSK9 in Vascular Tissues. Cardiovascular Research, 107(4): 556–567.
Zhiyong Q, Liang H, Jianjun Z, et al., 2021, PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation, 143(1): 45–61.
Qiang W, Bo Z, Peng C, et al., 2022, Leptin and PCSK9 Concentrations Are Associated with Vascular Endothelial Cytokines in Patients with Stable Coronary Heart Disease. Open Medicine (Wars), 17(1): 185–190.
Roshan MH, Tambo A, Pace NP, 2016, The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis. International Journal of Inflammation, 2016: 1532832.
De Winther MP, Kanters E, Kraal G, et al., 2005, Nuclear Factor Kappa B Signaling in Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5): 904–914.
Ricci C, Ruscica M, Camera M, et al., 2018, PCSK9 Induces a Pro-Inflammatory Response in Macrophages. Scientific Reports, 8(1): 2267.
Zhihan T, Juan P, Zhong R, et al., 2017, New Role of PCSK9 in Atherosclerotic Inflammation Promotion Involving the TLR4/NF-kB Pathway. Atherosclerosis, 262: 113–122.
Scalise V, Sanguinetti C, Neri T, et al., 2021, PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NF-kB Signaling. International Journal of Molecular Sciences, 22(23): 12640.
Zufeng D, Shijie L, Xianwei W, et al., 2015, Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta. Antioxidants & Redox Signaling, 22(9): 760–771.
Zhihan T, Lu J, Juan P, et al., 2012, PCSK9 siRNA Suppresses the Inflammatory Response Induced by OxLDL Through Inhibition of NF-kB Activation in THP-1-Derived Macrophages. International Journal of Molecular Medicine, 30(4): 931–938.
Kühnast S, Hoorn JWV, Pieterman EJ, et al., 2014, Alirocumab Inhibits Atherosclerosis, Improves Plaque Morphology, and Enhances the Effects of a Statin. Journal of Lipid Research, 55(10): 2103–2112.
Landlinger C, Pouwer MG, Juno C, et al., 2017, The ATO4A Vaccine Against Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Total Cholesterol, Vascular Inflammation, and Atherosclerosis in APOE 3Leiden.CETP Mice. European Heart Journal, 38(32): 2499–2507.
Scicali R, Pino AD, Ferrara V, et al., 2021, Effect of PCSK9 Inhibitors on Pulse Wave Velocity and Monocyte-to-HDL Cholesterol Ratio in Familial Hypercholesterolemia Subjects: Results From a Single Lipid Unit Real-Life Setting. Acta Diabetologica, 58(7): 949–957.
Bernelot Moens SJ, Neele AE, et al., (2017), PCSK9 Monoclonal Antibodies Reverse the Pro-Inflammatory Profile of Monocytes in Familial Hypercholesterolaemia. European Heart Journal, 38(20): 1584–1593.
Barale C, Bonomo K, Frascaroli C, et al., 2020, Platelet Function and Activation Markers in Primary Hypercholesterolemia Treated with Anti-PCSK9 Monoclonal Antibody: A 12-Month Follow-Up. Nutritional Metabolism and Cardiovascular Diseases, 30(2): 282–291.
Basiak M, Kosowski M, Hachula M, et al., 2022, Impact of PCSK9 Inhibition on Pro-Inflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque. Pharmaceuticals (Basel), 15(7): 802.
Li SS, Cao H, Shen DZ, et al., 2020, Effect of Quercetin on Atherosclerosis Based on Expressions of ABCA1, LXR-a, and PCSK9 in ApoE -/- Mice. Chinese Journal of Integrative Medicine, 26(2): 114–121.
Jia Q, Cao H, Shen D, et al., 2019, Quercetin Protects Against Atherosclerosis by Regulating the Expression of PCSK9, CD36, PPARγ, LXRα, and ABCAI. International Journal of Molecular Medicine, 44(3): 893–902.
Cao C, Su M, 2019, Effects of Berberine on Glucose-Lipid Metabolism, Inflammatory Factors and Insulin Resistance in Patients With Metabolic Syndrome. Experimental and Therapeutic Medicine, 17(4): 3009–3014.
Meng S, Wang LS, Huang ZQ, et al., 2012, Berberine Ameliorates Inflammation in Patients With Acute Coronary Syndrome Following Percutaneous Coronary Intervention. Clinical and Experimental Pharmacology and Physiology, 39(5): 406–411.
Ma CY, Shi XY, Wu YR, et al., 2021, Berberine Attenuates Atherosclerotic Lesions and Hepatic Steatosis in ApoE–/– Mice by Down-Regulating PCSK9 via the ERK1/2 Pathway. Annals of Translational Medicine, 9(20): 1517.
Xiao HB, Sun ZL, Zhang HB, et al., 2012, Berberine Inhibits Dyslipidemia in C57BL/6 Mice With Lipopolysaccharide-Induced Inflammation. Pharmacological Reports, 64(4): 889–895.
Huang YP, Wang YS, Liu YY, et al., 2022, Chemical Characterization and Atherosclerosis Alleviation Effects of Gypenosides From Gynostemma Pentaphyllum Through Ameliorating Endothelial Dysfunction via the PCSK9/LOX1 Pathway. Journal of Agricultural and Food Chemistry, 70(38): 11944–11957.
Majeed ML, Ghafil FA, Fatima G, et al., 2021, Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian Journal of Clinical Biochemistry, 36(1): 74–80.
El-Seweidy MM, Amin Rs, Atteia HH, et al., 2019, Dyslipidemia-Induced Inflammatory Status, Platelet Activation and Endothelial Dysfunction in Rabbits: Protective Role of 10-Dehydrogingerdione. Biomedical Pharmacotherapy, 110: 456–464.
Elseweidy MM, ElSwefy SE, Younis NN, et al., 2020, The Modulation of PCSK9 and GAGs by 10-Dehydrogingerdione and Pentoxifylline in Hyperlipidemic Rabbits. Natural Product Research, 34(16): 2372–2377.
Elseweidy MM, ElSwefy SE, Younis NN, et al., 2019, Contribution of Aorta Glycosaminoglycans and PCSK9 to Hyperlipidemia in Experimental Rabbits: The Role of 10-Dehydrogingerdione as an Effective Modulator. Molecular Biology Reports, 46(4): 3921–3928.
Elseweidy MM, Amin RS, Atteia HH, et al., 2018, New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition. Applied Biochemistry and Biotechnology, 186(4): 805–815.
Gang W, Zhenbin L, Menghu L, et al., 2019, Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK9 Expression and Functionality. Biomedical Research International, 2019: 7284767.
Viswanatha GL, Shylaja H, Keni R, et al., 2022, A Systematic Review and Meta-Analysis on the Cardioprotective Activity of Naringin Based on Pre-Clinical Evidences. Phytotherapy Research, 36(3): 1064–1092.
Olumegbon LT, Lawal AO, Oluyede DM, et al., 2022, Hesperetin Protects Against Diesel Exhaust Particles-Induced Cardiovascular Oxidative Stress and Inflammation in Wistar Rats. Environmental Science and Pollution Research International, 29(35): 52574–52589.
He LF, Wang C, Zhang YF, et al., 2022, Effect of Emodin on Hyperlipidemia and Hepatic Lipid Metabolism in Zebrafish Larvae Fed a High-Cholesterol Diet. Chemistry and Biodiversity, 19(2): e202100675.
Chenhui Z, Zuan L, Liyuan K, et al., 2021, Recent Research Progress (2015–2021) and Perspectives on the Pharmacological Effects and Mechanisms of Tanshinone I A. Frontiers in Pharmacology, 12: 778847.
Yang Y, Pan C, Zhang M, et al., 2018, Effects of Evodiamine on NARC-1/PCSK9 Expression in Atherosclerotic Rabbits. Pharmacology and Clinics of Chinese Materia Medica, 34(6): 27–30.
Wang Y, Yang W, Peng F, et al., 2019, Evodiamine Inhibits Lipopolysaccharide-Induced Human Umbilical Vein Endothelial Cell Injury Through TLR4/NF-kB Pathway. Journal of Cellular and Molecular Immunology, 35(12): 1088–1093.
Gao N, Yang Q, 2017, Study on the Preventive Effect of Resveratrol on Hyperlipidemia Model Mice and the Improvement Effect on Model Golden Hamsters. China Pharmacy, 28(31): 4393–4397.
Li S, Li Q, Zhou C, et al., 2022, Resveratrol Regulates NLRP3 Inflammasome-Mediated Pyroptosis of Vascular Smooth Muscle Cells to Resist Atherosclerosis. Drug Evaluation Research, 45(10): 1972–1979.
Sun S, Zhang Z, Qiao Y, et al., 2018, Effects of Astragalus Polysaccharides on Inflammatory Factors in Atherosclerosis of ApoE’ Mice. Preventive Medicine Forum, 24(6): 407–408.
Zou H, Liu Z, 2017, Effect of Astragalus Polysaccharides on the Expression of Proprotein Convertase Subtilisin/Kexin Type 9 in THP-1 Cells. Chinese Journal of Biologicals, 30(2): 157–162.
Huiming H, Jiajun W, Can C, et al., 2022, The Hypolipidemic Effect of Hawthorn Leaf Flavonoids Through Modulating Lipid Metabolism and Gut Microbiota in Hyperlipidemic Rats. Evidence-Based Complement and Alternative Medicine, 2022: 3033311.
Liu S, 2022, Effects of Total Flavonoids from Crataegus Leaf on Myocardial Lesions and Akt/Nrf2 Pathway in Myocardial Ischemia-Reperfusion Rats. Jilin Journal of Traditional Chinese Medicine, 42(5): 585–590.
Shanshan L, Hui C, Dingzhu S, et al., 2019, Efficacy of Shoushen Granule on Adenosine Triphosphate Binding Cassette Transporter A1, Proprotein Convertase Subtilisin/Kexin Type 9, and Toll-Like Receptor 4/Nuclear Factor Kappa-B Signaling Pathway in ApoE-Knockout Mice. Journal of Traditional Chinese Medicine, 39(4): 524–534.
Song Q, Fan R, Li Y, et al., 2021, Effects of Qizhi Tongmai Granules on PCSK9/LDLR Pathway in Rats with Dyslipidemia and Coronary Heart Disease. Chinese Journal of Emergency in Traditional Chinese Medicine, 30(11): 1920–1923.
Kong Y, Qin H, Wang Y, et al., 2021, Study on the Anti-Atherosclerotic Effect of Xueguan Ruanhua Pill by Regulating miR-17-5p and PCSK9/VLDLR Signaling Pathway. Journal of Anhui University of Chinese Medicine, 40(6): 69–75.
Liping Q, Didi L, Xiaoping G, et al., 2018, Di’ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9. Frontiers in Pharmacology, 9: 1170.
Jiyi L, Wei L, Honglin L, et al., 2022, Di’ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signaling Pathway. Frontiers in Pharmacology, 13: 857092.
Wang W, Liu L, 2018, Effects of Buyang Huanwu Decoction on Lipid Levels and SREBP-2/Pcsk9 Signaling Pathway in Hyperlipidemia Model Golden Hamsters. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 28(12): 1000–1008.
Wu N, Xu R, Li S, et al., 2015, Effects of Hedan Tablets on Lipid Profile, PCSK9 Levels, and High-Density Lipoprotein Particles in Patients with Hyperlipidemia. Chinese Journal of Arteriosclerosis, 23(12): 1277–1280.
Zhang W, Li G, Qi Q, et al., 2020, Regulatory Effect of Di’ao Xinxuekang on TLR4/MyD88/NF-kB Signaling Pathway in Atherosclerotic Rats. China Journal of Chinese Materia Medica, 45(3): 602–608.
Li Y, Lei Z, You Y, et al., 2023, Exploring the Mechanism of Buyang Huanwu Decoction in Regulating Macrophage Polarization Based on the TLR4/NF-kB/NLRP3 Pathway. Chinese Journal of Experimental Traditional Medical Formulas, 29(19): 18–25.
Sun L, Xu F, Ge Z, et al., 2017, Effects of Hedan Tablets on the Expression of IL-1β and TNF-α in Serum of Atherosclerotic ApoE Mice. Chinese Journal of Emergency in Traditional Chinese Medicine, 26(7): 1137–1140.
Zhang M, 2022, Exploring the Role and Mechanism of Huotan Jiedu Tongluo Recipe in Intervening Atherosclerotic Vulnerable Plaques Based on Endoplasmic Reticulum Autophagy-NLRP3 Inflammasome Signaling Pathway, thesis, Changchun University of Chinese Medicine.
Jiang X, Wang Z, 2021, Effects of Luhuang Granules on Serum LDL-C, PCSK9, and Liver Tissue NNMT, Sirt6, PCSK9, LDLR Gene Expression in ApoE’ Mice. Lishizhen Medicine and Materia Medica Research, 32(1): 51–53.
Liu C, Tang S, Sun Y, 2005, Effects of Luhuang Granules on C-Reactive Protein and Interleukin-6 Levels in Experimental Atherosclerotic Rabbits. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, 12(6): 366–368.